Previous 10 | Next 10 |
Aytu BioScience, Inc. (AYTU) Q1 2020 Earnings Conference Call November 14, 2019, 16:30 ET Company Participants Joshua Disbrow - Chairman & CEO David Green - CFO, Secretary & Treasurer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Carl Byr...
Aytu BioScience (NASDAQ: AYTU ): Q1 GAAP EPS of -$0.32 misses by $0.04 . More news on: Aytu BioScience, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
ENGLEWOOD, CO / ACCESSWIRE / November 14, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today will provide an overview of its business, including the company's operati...
ENGLEWOOD, CO / ACCESSWIRE / November 11, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the hiring of Matthew Phillips as the company's Executive Vice ...
ENGLEWOOD, CO / ACCESSWIRE / November 7, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced that the company will present its operational results for the qu...
Asset Purchase Increases Combined Company Annual Revenue to $44M, Including Previously Announced Acquisition of Innovus Pharmaceuticals Over $5 Million in Near-Term Cost Savings Expected Through Efficient Sales Force Integration and Removal of Redundant Operations ENGLEWOOD, CO / A...
Tuzistra XR Now Covered on Commercial Plans Covering Over 30 Million U.S. Lives U.S. Cough Cold Prescription Market is Worth in Excess of $3 Billion at Current Brand Pricing, with 30-35 Million Prescriptions Written Annually ENGLEWOOD, CO / ACCESSWIRE / October 21, 2019 / Aytu BioS...
Phase IV, Investigator-Initiated Study is First to Conclusively Show that a Testosterone Replacement Therapy (TRT) Maintains Key Fertility Measures in Men with Low T Natesto Increased Serum Testosterone and Improved Hypogonadal Symptoms While Simultaneously Maintaining Semen Parameters ...
Investigator-initiated, Phase IV study results will be presented today at 75 th Annual American Society for Reproductive Medicine (ASRM) scientific conference ‘Late Breaking' abstract session ENGLEWOOD, CO / ACCESSWIRE / October 16, 2019 / Aytu BioScience, Inc. (NASDAQ:AYTU), a ...
The following slide deck was published by Aytu BioScience, Inc. in conjunction with this Read more ...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...